- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02760199
89Zr-AMG211 PET Imaging Study
89Zr-AMG211 PET Imaging in Patients With Relapsed/Refractory Gastrointestinal Adenocarcinoma Before and During Treatment With AMG 211
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1081 HV
- VUMC
-
Groningen, Netherlands, 9713 GZ
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject will or is also participating in the ongoing phase 1 study in which AMG 211 is administered via cIV. 89Zr-AMG211 PET imaging will be performed before and/or during treatment with AMG 211 cIV
- Informed consent provided
- Male or Female ≥ 18 years of age at the time of informed consent
- Advanced relapsed/refractory gastrointestinal adenocarcinoma
At least 1 measurable tumor lesion
o In case the investigators do not find any uptake in metastatic liver lesions in the first set of patients on the 89Zr-AMG211 PET scan, than subsequent patients need to have at least 1 measurable tumor lesion outside the liver
- Archival tumor tissue available or is willing to undergo biopsy of a tumor lesion before the start of treatment
- Adequate hematological, renal, and liver function
- Body weight ≥ 45 kg
- Other inclusion criteria may apply
Exclusion Criteria:
- Malignancy other than GI adenocarcinoma requiring current therapy
- Evidence of uncontrolled systemic disease (other than GI adenocarcinoma), active infection, Hepatitis B and/or C, HIV, history of cardiac disease, history of significant central nervous system (CNS) disease, history of chronic autoimmune disease (with the exception of stable type 1 diabetes)
- Major surgery within 28 days of study day 1
Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment in another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
o Exception to this criterion is the participation in the currently ongoing phase 1 study with AMG 211 cIV and all procedures related to this study.
- Treatment with any chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal therapy for cancer within 14 days prior to study entry or not recovered from treatment
- Unresolved toxicities from prior anti-tumor therapy
- Males or Females of reproductive potential and unwilling to practice an acceptable method of effective birth control while on study through 30 days after receiving the last dose of study drug.
- Females who are pregnant, planning to become pregnant, lactating/breastfeeding or who plan to breastfeed while on study through 30 days after receiving the last dose of study drug
- Other exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 89Zr-AMG211 and 89Zr-AMG211 PET
|
Injection of 89Zr-AMG211 for imaging.
89Zr-AMG211 PET scan(s).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The quantitative uptake op 89Zr-AMG211 in tumor tissue, organs and blood circulation expressed in SUV (Standardized Uptake Value)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response to AMG 211 therapy according to the immune related response criteria (irRC) will be correlated to 89Zr-AMG211 tumor uptake data (measured in SUV).
Time Frame: 1 year
|
1 year
|
Number of patients with adverse events after 89Zr-AMG211 injection as a measure of safety and tolerability. Incidence, nature and severity of adverse events (according to CTCAE version 4.03) will be measured.
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Explore the target tissue saturation by AMG 211, defined as changes in tissue uptake of radioactivity concentration, and correlate it with pharmacokinetics.
Time Frame: 1 year
|
1 year
|
Evaluate 89Zr-AMG211 as a complementary tool for improved patient selection for targeted therapy with AMG 211.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20150930
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Gastrointestinal Cancer
-
Sumitomo Pharma America, Inc.CompletedAdvanced Gastrointestinal CancerUnited States, Canada
-
Goethe UniversityAgaplesion Markus Krankenhaus gGmbHCompletedAdvanced Gastrointestinal CancerGermany
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Apceth GmbH & Co. KGTerminatedAdvanced Gastrointestinal CancerGermany
-
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.RecruitingAdvanced Breast Cancer | Advanced Solid Tumor | Advanced Gastric CancerUnited States
-
Duke UniversityNational Institutes of Health (NIH)Not yet recruitingAdvanced Cancer | Gastrointestinal Cancer
-
Peking UniversityRecruitingAdvanced or Late Stage Gastrointestinal CancerChina
-
Krankenhaus NordwestCompletedAdvanced Gastric Cancer | Advanced Cancer of the Esophagogastric JunctionGermany
-
Case Comprehensive Cancer CenterCompletedStage IV Gastrointestinal Cancer | Advanced Gynecological CancerUnited States
-
Royal Marsden NHS Foundation TrustUnknownAdvanced Gastrointestinal CancersUnited Kingdom
Clinical Trials on 89Zr-AMG211
-
Telix International Pty LtdCompletedClear Cell Renal Cell CarcinomaUnited Kingdom, United States, Australia, Turkey, Netherlands, Belgium, Canada, France
-
Telix International Pty LtdCompletedCarcinoma, Renal Cell | Clear Cell Renal Cell CarcinomaJapan
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
Affiliated Hospital of Jiangnan UniversityRecruiting
-
South Metropolitan Health ServiceTelix International Pty LtdRecruiting
-
Wuxi No. 4 People's HospitalNot yet recruitingSolid Tumor, AdultChina
-
Wuxi No. 4 People's HospitalUnknownSolid Tumor, AdultChina
-
Radboud University Medical CenterABX CRO; Telix International Pty LtdCompleted
-
Memorial Sloan Kettering Cancer CenterGenentech, Inc.Completed
-
Affiliated Hospital of Jiangnan UniversityRecruiting